THRX : Analysis & Opinions

  1. Theravance Inc. (THRX): New Analyst Report from Zacks Equity ...

    January 13, 2015
    Theravance's third-quarter 2014 loss of $0.19 per share was wider than the Zacks Consensus Estimate of a loss of $0.15. Theravance ...
  2. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  3. A Value Guru Is Loading Up On These 2 Biotech Stocks

    November 20, 2013
    "There's no shame in holding cash."It's a refrain you hear from many fund managers these days after witnessing the market ...
  4. Elan Shareholders Bring Management To Heel

    June 17, 2013
    The rejection of Elan management's proposed transactions ought to accelerate the sale of the company.
  5. AstraZeneca Pays Up To Patch Up Another Key Area

    June 10, 2013
    In buying Pearl, AstraZeneca is taking some of the risk out of its valuable COPD franchise.
  6. Elan Continues To Make Baffling Strategic Decision

    May 21, 2013
    Elan seems to be set on wasting the Tysabri windfall instead of returning it to shareholders
  7. Glaxo Invests in Nigeria - Analyst Blog

    November 28, 2012
    GlaxoSmithKline (GSK) recently announced that it has reached an agreement with GlaxoSmithKline Consumer Nigeria plc regarding ...
  8. Eli Lilly Among Healthcare's Biggest Movers on August 27, 2012

    August 27, 2012
    The market is on the rise this morning. The Nasdaq is up 0.5%; the S&P 500 has risen 0.3%; and the Dow has climbed 0.1%. ...
  9. Biggest Healthcare Sector Movers for July 3, 2012

    July 3, 2012
    The market is doing well so far today. The Nasdaq has moved up 0.7%; the S&P 500 is up 0.7%; and the Dow has risen 0.6%. ...
  10. Seth Klarman's Biggest Bets

    December 8, 2009
    It's always a good idea to watch the pros, especially guys like Seth Klarman.
Trading Center